http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고지방혈중에서 Bezafibrate ( Bezalip(R)) 의 효과에 대한 연구
이웅구(Woong Ku Lee),김병옥(Byung Ok Kim),조현명(Hyeon Myeong Cho),장양수(Yang Soo Jang),정남식(Nam Sik Chung),심원흠(Won Heum Shim),조승연(Seung Yun Cho),김성순(Sung Soon Kim),양주영(Joo Young Yang) 대한내과학회 1991 대한내과학회지 Vol.40 No.6
N/A Among the risk factors associated with coronary artery disease, hyperlipidemia is one of the most important. Bezafibrate has been shown to effctively reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) in hyperlipidemia. It has also been claimd to be particularly effective in increasing high-density lipoprotein (HDL) concentrations. In the present study, 22 hyperlipidemic patients were investigated before and after 8 weeks treatment with bezafibrate (300 mg to 400 mg daily) in an effort to clarify futher the effects and side effects of the drug. In the group of 9 patients with hypertriglyceridemia (TG level>230mg%), the serum triglycerides decreased by 63%(p<0.01) and the HDL cholesterol increased by 45%, (p<0.01) corresponding to a significant reduction of total cholesterol/HDL cholesterol ratio. In the group of 9 patients with hypercholesterolemia (cholesterol level > 240 mg%), the total cholesterol decreased by 20% (p<0.01), the LDL cholesterol decreased by 25% (p<0.01) and HDL cholestrol increased by 44% (p<0.01) corresponding to a significant reduction of LDL/HDL ratio. In the group of 4 patients with combined hyperlipidemia (TG level > 230 mg% and cholesterol level > 240 mg%), the total cholesterol decreased by 23% (p<0.01), the serum triglyceride decreased by 62% (p<0.01) and the HDL-cholesterol increased by 19% (p<0.05) corresponding to a significant reduction of total cholesterol/HDL cholesterol ratio. In the total of 22 patients, the total cholesterol decreased by 15% (p<0.05), the serum triglyceride decreased by 59% (p<0.01) and the HDL cholesterol increased by 39% (p <0. 01) corresponding to a significant reduction of total cholesterol/HDL cholesterol ratio. No subjective side effects were noted from the drug, except in one patient with mild gastrointestinal symptoms. In conclusion, it was noted that the bezafibrate was an effective and safe drug useful in the treatment of hyperlipidemia in Korean adult patients.
급성 심근경색증 환자에서 혈전용해제 ( Urokinase ) 투여 및 경피적경혈관 관동맥확장성형술
이웅구(Woong Ku Lee),심원흠(Won Heum Shim),조승연(Seung Yun Cho),박승정(Seung Jung Park),정상만(Sang Man Chung),김성순(Sung Soon Kim) 대한내과학회 1988 대한내과학회지 Vol.34 No.2
N/A Since percutaneous transluminal coronary angiolplasty (PTCA) was introduced by Gruenzig in 1977, this procedure was extended to the multi-vessel lesion, unstable angina, acute myocardial infarction and old myocardial infarction. We performed coronary angiography and PTCA in 17 patients with evolving acute myocardial infarction for the last 21 months from February 1986 to November 1987 at Severance Hospital, Yonsei University. The result are followings: 1) Fifteen of 17 patients (88.2%) with total coronary occlusion underwent successful PTCA, including 15 patients with and 2 patients without previous intravenous or intracoronary urokinase infusion. 2) One patient (6.0%) died due to cardiogenic shock. 3) The delta area decreasing rate and left ventricular end diastolic pressure (LVEDP) were not improved in the left ventriculogram immediate after PTCA, but the LVEDP was significantly decreased in late follow-up left ventriculogram (Fig. 2,3). 4) In-hospital clinical course was stable in the 15 patients with successful PTCA, but 5 of them (33.3%) had angiographically restenosis during follow-up period of 2 days to 2 months. Two patients with angiographically restenosis and been performed repeat PTCA, one of them was successful. During follow-up period of 7 months (1-20 mos) in 15 patients with sucessful initial PTCA, 13 patients were in functional class I, two was functional class II and no death. 5) The patency rate of infarct-related coronary artery after urokinase infusion was 26.7%. The immediate urokinase effects was not remarkable in this study. These data suggest that successful PTCA with sustained patency of an infarct-related artery has a beneficial effect on the salvage of the jeopardized myocardium. In conclusion PTCA with or without thrombolytic therapy can be carried out with safety and is potentially useful therapeutic procedure in management of selected patients in evolving acute myocardial infarction.